All data are based on the daily closing price as of September 1, 2025
h

Hisamitsu Pharmaceutical

4530.TSE
29.18 USD
0.56
+1.96%

Overview

Last close
29.18 usd
Market cap
2.08B usd
52 week high
32.23 usd
52 week low
22.74 usd
Target price
29.59 usd

Valuation

P/E
15.798
Forward P/E
N/A
Price/Sales
1.9362
Price/Book Value
1.109
Enterprise Value
1.25B usd
EV/Revenue
1.1905
EV/EBITDA
7.2061

Key financials

Revenue TTM
1.05B usd
Gross Profit TTM
623.53M usd
EBITDA TTM
168.25M usd
Earnings per Share
1.81 usd
Dividend
0.58 usd
Total assets
334.93B usd
Net debt
-101.46B usd

About

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United States of America, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
  • Symbol
    4530.TSE
  • Exchange
    TSE
  • Isin
    JP3784600003
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Kazuhide Nakatomi
  • Headquarter
    Tosu
  • Web site
    https://www.global.hisamitsu
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top